Recent Finacing
Recent Raise
CastleVax develops a clinical-stage intranasal NDV-vectored COVID-19 vaccine (CVAX-01), conducting a 10,000-participant Phase 2b trial comparing intranasal to intramuscular vaccination; platform licensed from Mount Sinai.
